PA5-37755

antibody from Invitrogen Antibodies

Targeting: TGFBR2 MFS2, TBR-ii, TBRII

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-37755

Provider

Invitrogen Antibodies

Product name

Phospho-TGFBR2 (Ser225, Ser250) Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control for IHC is human brain tissue.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20°C

References

Submitted references

Activation of BK Channels Prevents Hepatic Stellate Cell Activation and Liver Fibrosis Through the Suppression of TGFβ1/SMAD3 and JAK/STAT3 Profibrotic Signaling Pathways.

Yang L, Han B, Zhang M, Wang YH, Tao K, Zhu MX, He K, Zhang ZG, Hou S
Frontiers in pharmacology 2020;11:165

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of Phospho-TGFBR2 (Ser225, Ser250) in paraffin-embedded Human brain tissue using Phospho-TGFBR2 (Ser225, Ser250) Polyclonal Antibody (Product # PA5-37755) (left) or the same antibody preincubated with blocking peptide (right).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 5 Rottlerin exerts antifibrotic effects through inhibition of the TGFbeta1/SMAD3 signaling pathway. (A) SMAD activity as measured by luciferase reporter assay using reporter vectors PGL4.48[luc2P/SBE/Hygro] in LX2 cells with the indicated treatments. SBE means SMAD binding element (** p < 0.01 compared with the vehicle (Veh) group, ## p < 0.01 compared with the TGFbeta1-treated group; n = 3). (B) Representative western blots ( left ) and normalized intensity ( right ) of the p-SMAD3 levels in primary hepatic stellate cells (HSCs) treated as indicated. Phosphorylation levels of the SMAD3 protein were measured in serum-starved HSCs treated with TGFbeta1 (4 ng/mL) for 1 h. Rottlerin (3 muM) was applied to the medium for 6 h before TGFbeta1 application ( * p < 0.05 compared with the Veh group, # p < 0.05 compared with the TGFbeta1-treated group, n = 3). (C) Representative western blots ( left ) and normalized intensity ( right ) of the levels of total and/or phosphorylated proteins, as indicated, in liver tissues from vehicle, CCl 4 , and rottlerin-treated rats with CCl 4 -induced fibrosis (** p < 0.01 compared with the Veh group, # p < 0.05, and ## p < 0.01 compared with the CCl 4 -treated group, n = 3).